{ "schemaVersion": 2, "eyebrow": "Cardiology", "title": "AF Cardioversion Anticoagulation", "summary": "For elective cardioversion of atrial fibrillation lasting 48 hours or longer or of uncertain duration, establish uninterrupted therapeutic anticoagulation for 3 weeks or exclude intracardiac thrombus by imaging, then continue anticoagulation for at least 4 weeks after restoration of sinus rhythm.", "seoDescription": "Practical anticoagulation and TEE strategy for atrial fibrillation cardioversion, including timing, left atrial appendage thrombus, and postprocedure therapy.", "clinicalQuestion": "How should anticoagulation and imaging be used to prevent thromboembolism around atrial fibrillation cardioversion?", "specialty": "Cardiology", "audience": "U.S. physicians and medical trainees", "tags": [ "atrial fibrillation cardioversion", "cardioversion anticoagulation", "TEE-guided cardioversion", "left atrial appendage thrombus", "DOAC cardioversion" ], "keyTakeaways": [ "For elective cardioversion when AF duration is 48 hours or longer, use 3 weeks of uninterrupted therapeutic anticoagulation or preprocedural imaging that excludes intracardiac thrombus. [15]", "Establish therapeutic anticoagulation before electrical or pharmacologic cardioversion and continue it without interruption for at least 4 weeks afterward. [15]", "If imaging identifies left atrial appendage thrombus, defer cardioversion, give therapeutic anticoagulation for 3 to 6 weeks, and repeat imaging before reconsidering cardioversion. [15]", "DOACs are reasonable alternatives to vitamin K antagonists and may be preferred when not contraindicated because therapeutic effect is rapid and treatment continuity is more reliable. [15]", "A negative TEE does not eliminate the need for post-cardioversion anticoagulation because atrial stunning and early recurrence contribute to postprocedure thromboembolic risk. [15][20]" ], "sections": [ { "id": "initial-cardioversion-decision", "eyebrow": "Preprocedure triage", "heading": "Classify AF duration before scheduling elective cardioversion", "intro": "Duration and anticoagulation continuity determine whether elective cardioversion can proceed.", "paragraphs": [ "For AF documented as lasting 48 hours or longer, use either of two pathways before elective electrical or pharmacologic cardioversion: uninterrupted therapeutic oral anticoagulation for 3 weeks, or imaging to exclude intracardiac thrombus. The thromboembolic precautions apply equally to pharmacologic and electrical cardioversion. [15]", "Treat an uncertain onset time as a thrombus-risk scenario rather than relying on symptom onset alone. Contemporary practice commonly uses TEE to exclude left atrial or left atrial appendage thrombus when expedited cardioversion is needed and adequate preceding anticoagulation has not been completed. [3][4][15]", "Do not use successful restoration of sinus rhythm as a reason to abbreviate anticoagulation. Cardioversion can embolize pre-existing thrombus and is followed by atrial mechanical dysfunction, or atrial stunning, and a transient prothrombotic state. [15]" ], "bullets": [ "Elective AF cardioversion at 48 hours or longer: document either 3 weeks of uninterrupted therapeutic anticoagulation or imaging excluding intracardiac thrombus. [15]", "For an expedited strategy, obtain preprocedural imaging rather than proceeding on the basis of short-lived symptom reporting. [3][15]", "Apply the same pericardioversion thromboembolic strategy to chemical and electrical cardioversion. [15]" ], "subsections": [], "table": { "caption": "Anticoagulation pathways for elective AF cardioversion. [15]", "columns": [ "Clinical situation", "Action before cardioversion", "Action after cardioversion" ], "rows": [ [ "AF duration at least 48 hours", "Complete 3 weeks of uninterrupted therapeutic anticoagulation, or perform imaging to exclude intracardiac thrombus. [15]", "Continue therapeutic anticoagulation without interruption for at least 4 weeks. [15]" ], [ "AF onset uncertain", "Use the same 3-week anticoagulation or imaging-exclusion pathway before elective cardioversion. [3][15]", "Continue therapeutic anticoagulation without interruption for at least 4 weeks. [15]" ], [ "Intracardiac or LAA thrombus found", "Defer cardioversion; institute therapeutic anticoagulation for 3 to 6 weeks and repeat imaging. [15]", "Proceed only after repeat imaging informs the decision; maintain anticoagulation as indicated. [15]" ] ] } }, { "id": "choice-of-anticoagulant", "eyebrow": "Drug selection", "heading": "Choose a therapeutic anticoagulant that can be maintained without interruption", "intro": "The procedural requirement is continuous therapeutic anticoagulation, not a specific rhythm-control modality.", "paragraphs": [ "DOACs are accepted alternatives to vitamin K antagonists for thromboprophylaxis around cardioversion. In patients without a contraindication to DOAC therapy, their rapid onset, reliable maintenance of therapeutic effect, and ease of continuation make them a preferred practical option in the ACC/AHA/ACCP/HRS guideline discussion. [15]", "If warfarin is used, ensure therapeutic anticoagulation rather than counting calendar time alone. The cardioversion literature describes warfarin therapy with therapeutic INR 2.0 to 3.0; interruption or subtherapeutic anticoagulation undermines the conventional delayed-cardioversion pathway. [21][22]", "Do not substitute aspirin for therapeutic anticoagulation when cardioversion-related embolic protection is required. Adjusted-dose warfarin is substantially more efficacious than aspirin for stroke prevention in AF, and current cardioversion guidance specifies therapeutic anticoagulation before and after the procedure. [9][15]" ], "bullets": [ "Select a DOAC when clinically suitable and when adherence can be assured through the pre- and post-cardioversion intervals. [15]", "For warfarin, verify that anticoagulation is therapeutic; INR 2.0 to 3.0 is the described therapeutic range. [21][22]", "Plan anticoagulant access and adherence before scheduling cardioversion because the 4-week postprocedure course should not be interrupted. [15]" ], "subsections": [], "table": { "caption": "Anticoagulant considerations around AF cardioversion. [15][21][22]", "columns": [ "Option", "Practical pericardioversion use", "Key limitation" ], "rows": [ [ "DOAC", "May be used for cardioversion thromboprophylaxis and may be preferred when not contraindicated because therapeutic effect is rapid and continuation is straightforward. [15]", "Requires reliable uninterrupted use throughout the planned strategy. [15]" ], [ "Warfarin", "Use as therapeutic anticoagulation; cardioversion literature describes a therapeutic INR of 2.0 to 3.0. [21][22]", "A subtherapeutic INR or interruption prevents reliance on a completed therapeutic-anticoagulation pathway. [21]" ] ] } }, { "id": "tee-guided-cardioversion", "eyebrow": "Expedited pathway", "heading": "Use TEE when cardioversion cannot wait for 3 weeks of anticoagulation", "intro": "TEE changes management only if it determines whether cardioversion can proceed safely.", "paragraphs": [ "TEE-guided cardioversion is the alternative to waiting through the 3-week anticoagulation interval when AF is 48 hours or longer or onset is uncertain. A study of anticoagulated AF/AFL populations found a mean-weighted left atrial thrombus prevalence of 2.73%, emphasizing that anticoagulation exposure lowers but does not abolish thrombus risk. [12][15]", "Use heightened caution in patients with nonparoxysmal AF/AFL or CHA2DS2-VASc score of 3 or greater. In the cited systematic review, left atrial thrombus prevalence was 4.81% in nonparoxysmal versus lower prevalence in paroxysmal AF/AFL, and 6.31% among those with CHA2DS2-VASc scores of 3 or greater. [12]", "If TEE excludes intracardiac thrombus, cardioversion may proceed under therapeutic anticoagulation, but continue anticoagulation for at least 4 weeks afterward. A negative study addresses pre-existing thrombus; it does not prevent embolic risk related to post-cardioversion atrial stunning or early AF recurrence. [15][20]" ], "bullets": [ "Use TEE to enable expedited cardioversion when the preceding 3-week uninterrupted-anticoagulation requirement has not been met. [15]", "Do not regard a negative TEE as a reason to omit the 4-week post-cardioversion anticoagulation interval. [15]", "Anticipate greater yield for TEE in nonparoxysmal AF/AFL and in CHA2DS2-VASc score 3 or greater. [12]" ], "subsections": [], "table": { "caption": "How TEE findings change the cardioversion plan. [12][15]", "columns": [ "TEE result", "Interpretation", "Next action" ], "rows": [ [ "No intracardiac thrombus", "Permits an expedited preprocedure strategy when therapeutic anticoagulation is established. [15]", "Proceed with cardioversion if otherwise appropriate; continue therapeutic anticoagulation for at least 4 weeks. [15]" ], [ "LAA or other intracardiac thrombus", "Cardioversion-related embolic risk remains unacceptable. [15]", "Defer cardioversion; give therapeutic anticoagulation for 3 to 6 weeks, then repeat imaging. [15]" ], [ "No thrombus after prior 3 weeks of anticoagulation", "Residual thrombus is uncommon but not absent in anticoagulated populations. [12]", "Proceed according to the planned pathway and preserve uninterrupted postprocedure anticoagulation for at least 4 weeks. [15]" ] ] } }, { "id": "management-of-detected-thrombus", "eyebrow": "Procedure deferral", "heading": "Defer cardioversion when left atrial appendage thrombus is detected", "intro": "A detected thrombus changes the immediate objective from rhythm restoration to thrombus resolution.", "paragraphs": [ "When pre-cardioversion imaging detects LAA thrombus, do not proceed with cardioversion. Institute therapeutic anticoagulation for at least 3 to 6 weeks and repeat imaging before reconsidering cardioversion. [15]", "This repeat-imaging step is clinically consequential because left atrial thrombus can persist despite guideline-directed anticoagulation. Across studies of patients treated continuously for at least 3 weeks, mean-weighted prevalence was 2.73%; prevalence was higher in nonparoxysmal AF/AFL and in patients with CHA2DS2-VASc score 3 or greater. [12]", "Reassess the urgency of rhythm restoration while thrombus is treated. If cardioversion is no longer needed because symptoms or ventricular response are acceptable, avoid exposing the patient to a repeat procedure solely to document sinus rhythm; if cardioversion remains planned, use repeat imaging to determine whether the thrombus-related procedural barrier has resolved. [15]" ], "bullets": [ "Detected LAA thrombus: defer cardioversion. [15]", "Treat with therapeutic anticoagulation for 3 to 6 weeks before repeat imaging. [15]", "Use repeat imaging—not elapsed time alone—to reassess candidacy for cardioversion after a documented thrombus. [15]" ], "subsections": [], "table": null }, { "id": "post-cardioversion-anticoagulation", "eyebrow": "After the procedure", "heading": "Maintain anticoagulation for at least 4 weeks after cardioversion", "intro": "The postprocedure interval is required even when preprocedure imaging is negative.", "paragraphs": [ "Therapeutic anticoagulation should be established before cardioversion and continued without interruption for at least 4 weeks afterward. This recommendation applies to AF cardioversion regardless of whether the patient reached the procedure through 3 weeks of anticoagulation or through an imaging-guided strategy. [15]", "The early post-cardioversion period is a high-risk interval: thromboembolic events are concentrated during the first month and particularly within the first 10 days in reported clinical summaries. The biologic rationale includes atrial stunning after sinus rhythm restoration, possible embolization of previously present thrombus, early AF recurrence, and a transient prothrombotic state. [15][20]", "At the end of the mandatory 4-week interval, make the longer-term anticoagulation decision separately from the cardioversion decision, based on the patient's ongoing AF-related thromboembolic risk and clinical context. Do not let apparent maintenance of sinus rhythm alone substitute for longitudinal stroke-prevention assessment. [10][16]" ], "bullets": [ "Continue therapeutic anticoagulation for a minimum of 4 weeks after electrical or pharmacologic cardioversion. [15]", "Protect adherence especially during the first 10 days and throughout the first month, when post-cardioversion embolic events are concentrated. [20]", "Reassess the indication for longer-term anticoagulation after the pericardioversion minimum has been completed. [10][16]" ], "subsections": [], "table": null } ], "faq": [ { "question": "Does a negative TEE eliminate the need for 4 weeks of anticoagulation after cardioversion?", "answer": "No. A negative TEE excludes visualized pre-existing intracardiac thrombus but does not remove risk from post-cardioversion atrial stunning, early recurrence, and transient prothrombotic changes; continue therapeutic anticoagulation for at least 4 weeks. [15][20]" }, { "question": "What should be done if a left atrial appendage thrombus is found before cardioversion?", "answer": "Defer cardioversion, administer therapeutic anticoagulation for at least 3 to 6 weeks, and repeat imaging before reconsidering cardioversion. [15]" } ], "references": [ { "number": 1, "title": "Supplementary appendix - The Lancet", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/cms/10.1016/S0140-6736(16)31474-X/attachment/f977242e-5cb9-41d5-8cf0-7e83cc4bfce9/mmc1.pdf", "authors": "www.thelancet.com", "host": "www.thelancet.com" }, { "number": 2, "title": "Direct oral anticoagulants: evidence and unresolved issues", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)32439-9.pdf", "authors": "www.thelancet.com", "host": "www.thelancet.com" }, { "number": 3, "title": "Identifying Patients at High Risk of Left Atrial Appendage Thrombus Before Cardioversion: The CLOTS‐AF Score", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/full/10.1161/JAHA.122.029259?doi=10.1161%2FJAHA.122.029259", "authors": "www.ahajournals.org", "host": "www.ahajournals.org" }, { "number": 4, "title": "Preprocedural Multimodality Imaging in Atrial Fibrillation | Circulation", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.122.014386", "authors": "www.ahajournals.org", "host": "www.ahajournals.org" }, { "number": 5, "title": "2014 AHA/ACC/HRS Guideline for the Management of Patients With ...", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/10.1161/cir.0000000000000041", "authors": "www.ahajournals.org", "host": "www.ahajournals.org" }, { "number": 6, "title": "Identifying Patients at High Risk of Left Atrial Appendage Thrombus ...", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/pdf/10.1161/JAHA.122.029259", "authors": "www.ahajournals.org", "host": "www.ahajournals.org" }, { "number": 7, "title": "Management of Newly Detected Atrial Fibrillation: A Clinical Practice ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/0003-4819-139-12-200312160-00011", "authors": "www.acpjournals.org", "host": "www.acpjournals.org" }, { "number": 8, "title": "Atrial Fibrillation | Annals of Internal Medicine - ACP Journals", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/AITC201703070", "authors": "www.acpjournals.org", "host": "www.acpjournals.org" }, { "number": 9, "title": "Antithrombotic Therapy To Prevent Stroke in Patients with Atrial ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/0003-4819-131-7-199910050-00003", "authors": "www.acpjournals.org", "host": "www.acpjournals.org" }, { "number": 10, "title": "Analysis of The 2024 ESC/EACTS Guidelines For The Management ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S1053077024009170", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 11, "title": "Trigger-induced atrial fibrillation for the hospitalist: a review", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0953620526001810", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 12, "title": "Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0735109721047896", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 13, "title": "Spotlight on the 2024 ESC/EACTS management of atrial fibrillation guidelines: 10 novel key aspects", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11666470", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 14, "title": "Clinical Practice Guideline: Preventive Measures and Treatment Options for Atrial Fibrillation", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12580842", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 15, "title": "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11104284", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 16, "title": "2024 ESC Guidelines for the management of atrial fibrillation", "detail": "www.escardio.org", "url": "https://www.escardio.org/guidelines/clinical-practice-guidelines/all-esc-practice-guidelines/atrial-fibrillation", "authors": "www.escardio.org", "host": "www.escardio.org" }, { "number": 17, "title": "A comparative review of current international atrial fibrillation guidelines from a primary care perspective", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12258508", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 18, "title": "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines - PubMed", "detail": "pubmed.ncbi.nlm.nih.gov", "url": "https://pubmed.ncbi.nlm.nih.gov/38033089", "authors": "pubmed.ncbi.nlm.nih.gov", "host": "pubmed.ncbi.nlm.nih.gov" }, { "number": 19, "title": "Atrial Fibrillation - StatPearls - NCBI Bookshelf - NIH", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK526072", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 20, "title": "Cardioversion in Atrial Fibrillation - American College of Cardiology", "detail": "www.acc.org", "url": "https://www.acc.org/education-and-meetings/patient-case-quizzes/cardioversion-in-atrial-fibrillation", "authors": "www.acc.org", "host": "www.acc.org" }, { "number": 21, "title": "Anticoagulation in Atrial Fibrillation Cardioversion: What Is Crucial to Take into Account - PMC", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348761", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 22, "title": "Pharmacological Cardioversion - StatPearls - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/sites/books/NBK470536", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 23, "title": "[PDF] Atrial fibrillation: diagnosis and management | NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng196/resources/atrial-fibrillation-diagnosis-and-management-pdf-66142085507269", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 24, "title": "Atrial fibrillation: diagnosis and management | Guidance - NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng196/chapter/Recommendations", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "Supplementary appendix - The Lancet", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/cms/10.1016/S0140-6736(16)31474-X/attachment/f977242e-5cb9-41d5-8cf0-7e83cc4bfce9/mmc1.pdf", "authors": "www.thelancet.com", "host": "www.thelancet.com", "snippet": "Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b", "score": 0.46322632 }, { "number": 2, "title": "Direct oral anticoagulants: evidence and unresolved issues", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)32439-9.pdf", "authors": "www.thelancet.com", "host": "www.thelancet.com", "snippet": "Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight. Circulation 2019; 139", "score": 0.40344992 }, { "number": 3, "title": "Identifying Patients at High Risk of Left Atrial Appendage Thrombus Before Cardioversion: The CLOTS‐AF Score", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/full/10.1161/JAHA.122.029259?doi=10.1161%2FJAHA.122.029259", "authors": "www.ahajournals.org", "host": "www.ahajournals.org", "snippet": "Atrial fibrillation (AF) is associated with a 5‐fold increased risk of stroke and thromboembolism.1 Left atrial appendage thrombus (LAAT) is a common source of emboli and has been implicated in up to 90% of AF‐related strokes.2 To minimize the risk of thromboembolism, guideline‐directed anticoagulat", "score": 0.72814995 }, { "number": 4, "title": "Preprocedural Multimodality Imaging in Atrial Fibrillation | Circulation", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.122.014386", "authors": "www.ahajournals.org", "host": "www.ahajournals.org", "snippet": "Thus, TEE before cardioversion is used routinely in clinical practice to exclude LA thrombus in AF or atrial flutter of ≥48 hours' duration (or", "score": 0.72348577 }, { "number": 5, "title": "2014 AHA/ACC/HRS Guideline for the Management of Patients With ...", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/10.1161/cir.0000000000000041", "authors": "www.ahajournals.org", "host": "www.ahajournals.org", "snippet": "... anticoagulation is achieved before TEE and maintained after cardioversion for at least 4 weeks. ... in patients with atrial fibrillation", "score": 0.7018975 }, { "number": 6, "title": "Identifying Patients at High Risk of Left Atrial Appendage Thrombus ...", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/pdf/10.1161/JAHA.122.029259", "authors": "www.ahajournals.org", "host": "www.ahajournals.org", "snippet": "CHADS2 and CHA2DS2-. VASc score of patients with atrial fibrillation or flutter and newly detected left atrial thrombus. Clin Res Cardiol. 2013;102:139– 144", "score": 0.6578248 }, { "number": 7, "title": "Management of Newly Detected Atrial Fibrillation: A Clinical Practice ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/0003-4819-139-12-200312160-00011", "authors": "www.acpjournals.org", "host": "www.acpjournals.org", "snippet": "Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis.", "score": 0.53997856 }, { "number": 8, "title": "Atrial Fibrillation | Annals of Internal Medicine - ACP Journals", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/AITC201703070", "authors": "www.acpjournals.org", "host": "www.acpjournals.org", "snippet": "Warfarin is the traditional choice for anticoagulation in patients with atrial fibrillation, and the dose should be adjusted to an international", "score": 0.42792314 }, { "number": 9, "title": "Antithrombotic Therapy To Prevent Stroke in Patients with Atrial ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/0003-4819-131-7-199910050-00003", "authors": "www.acpjournals.org", "host": "www.acpjournals.org", "snippet": "Adjusted-dose warfarin and aspirin reduce stroke in patients with atrial fibrillation, and warfarin is substantially more efficacious than", "score": 0.28409457 }, { "number": 10, "title": "Analysis of The 2024 ESC/EACTS Guidelines For The Management ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S1053077024009170", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "## Conclusions\n\nThe 2024 ESC guidelines for AF management introduce the AF-CARE pathway, advancing the prior ABC framework to deliver a holistic, patient-centered approach. This pathway supports comprehensive care by integrating comorbidity management, stroke prevention, symptom reduction through ra", "score": 0.76512027 }, { "number": 11, "title": "Trigger-induced atrial fibrillation for the hospitalist: a review", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0953620526001810", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Previous article in issue\n Next article in issue\n\n## Keywords\n\nAtrial fibrillation\n\nAcute illness\n\nAnticoagulation\n\nRate control\n\nRhythm control\n\nShared decision-making\n\n## Abbreviations\n\nACC\n\nAmerican College of Cardiology\n\nACCP\n\nAmerican College of Chest Physicians\n\nAF\n\natrial fibrillation\n\nAHA\n", "score": 0.44333586 }, { "number": 12, "title": "Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0735109721047896", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation\n## Journal of the American College of Cardiology. Image 4: Journal of the American College of Cardiology. Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation. Cardiac Amyl", "score": 0.7845341 }, { "number": 13, "title": "Spotlight on the 2024 ESC/EACTS management of atrial fibrillation guidelines: 10 novel key aspects", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11666470", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "application. A significant shift is the new emphasis on comorbidity and risk factor control to reduce AF recurrence and progression. Individualized assessment of risk is suggested to guide the initiation of oral anticoagulation to prevent thromboembolism. New guidance is provided for anticoagulation", "score": 0.8805613 }, { "number": 14, "title": "Clinical Practice Guideline: Preventive Measures and Treatment Options for Atrial Fibrillation", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12580842", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "13.Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the ACC/AHA Joint committee on clinical practice guidelines. Circulation. 2024;149:e1–e156. doi: 10.1161/CIR.0000000000001193. [DOI] [PMC free article] [", "score": 0.8286204 }, { "number": 15, "title": "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11104284", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "Thromboembolic risks and considerations of anticoagulation apply to both pharmacological cardioversion and electrical cardioversion.23,24 Thromboembolic risks in the setting of acute cardioversion relate to preexisting thrombus, change in atrial mechanical function with restoration of sinus rhythm, ", "score": 0.82117355 }, { "number": 16, "title": "2024 ESC Guidelines for the management of atrial fibrillation", "detail": "www.escardio.org", "url": "https://www.escardio.org/guidelines/clinical-practice-guidelines/all-esc-practice-guidelines/atrial-fibrillation", "authors": "www.escardio.org", "host": "www.escardio.org", "snippet": "The task force developing the 2024 AF guidelines have made implementation a key goal by focusing on the underpinning evidence and using a consistent writing style for each recommendation (the intervention proposed, the population it should be applied to, and the potential value to the patient, follo", "score": 0.76554126 }, { "number": 17, "title": "A comparative review of current international atrial fibrillation guidelines from a primary care perspective", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12258508", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "## :4043-4140. doi: 10.1093/eurheartj/ehad192 [DOI] [PubMed] [Google Scholar]\n 2..Joglar JA, Chung MK, Armbruster AL, _et al_. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Co", "score": 0.7515939 }, { "number": 18, "title": "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines - PubMed", "detail": "pubmed.ncbi.nlm.nih.gov", "url": "https://pubmed.ncbi.nlm.nih.gov/38033089", "authors": "pubmed.ncbi.nlm.nih.gov", "host": "pubmed.ncbi.nlm.nih.gov", "snippet": "Show all (7)\n\n### ORCIDs linked to this article\n\n Marcus GM | 0000-0001-5197-7696\n Cronin EM | 0000-0001-5824-9106\n Chyou JY | 0000-0002-2990-8122\n\nCirculation, 30 Nov 2023, 149(1):e1-e156\n\n 38033089 PMCID: PMC11095842\n\nFree full text in Europe PMC\n\n This article has been corrected. See Circul", "score": 0.74363416 }, { "number": 19, "title": "Atrial Fibrillation - StatPearls - NCBI Bookshelf - NIH", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK526072", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Atrial fibrillation is the most common type of cardiac arrhythmia. It is the leading cardiac cause of stroke. Risk factors for atrial fibrillation include advanced age, high blood pressure, underlying heart and lung disease, congenital heart disease, and increased alcohol consumption. Although atria", "score": 0.2499142 }, { "number": 20, "title": "Cardioversion in Atrial Fibrillation - American College of Cardiology", "detail": "www.acc.org", "url": "https://www.acc.org/education-and-meetings/patient-case-quizzes/cardioversion-in-atrial-fibrillation", "authors": "www.acc.org", "host": "www.acc.org", "snippet": "that patients with an atrial fibrillation (AF) episode lasting greater than 48 hours should receive warfarin (class I, LOE B) or a non-vitamin K antagonist (apixaban, dabigatran, or rivaroxaban; class IIa, LOE C) for at least three weeks prior to and four weeks after cardioversion, regardless of CHA", "score": 0.78944516 }, { "number": 21, "title": "Anticoagulation in Atrial Fibrillation Cardioversion: What Is Crucial to Take into Account - PMC", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348761", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "of anticoagulation after the procedure in patients with AF duration > 48 h (or unknown) irrespective of CHA2DS2-VASc score or transesophageal echocardiography (TEE) done to exclude left atrial thrombi . [...] In patients with hemodynamic stability and an AF which lasted for longer than 48 h or of un", "score": 0.78944516 }, { "number": 22, "title": "Pharmacological Cardioversion - StatPearls - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/sites/books/NBK470536", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "This is most likely from atrial fibrillation or atrial flutter with variable heart block. Due to the risk of thrombus formation in the left atrial appendage during atrial fibrillation, cardioversion is rarely used in the emergency department. If the duration of the rhythm is less than 48 hours, the ", "score": 0.629889 }, { "number": 23, "title": "[PDF] Atrial fibrillation: diagnosis and management | NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng196/resources/atrial-fibrillation-diagnosis-and-management-pdf-66142085507269", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "in decisions about medicines in NICE's guideline on medicines adherence and patient decision aids in NICE's guideline on medicines optimisation. • Take into account any contraindications for each drug and follow the guidance in the British National Formulary and the MHRA advice on direct-acting oral", "score": 0.7872945 }, { "number": 24, "title": "Atrial fibrillation: diagnosis and management | Guidance - NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng196/chapter/Recommendations", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "##### 1.6.4\n\nConsider anticoagulation with a direct‑acting oral anticoagulant for men with atrial fibrillation and a CHA2DS2‑VASc score of 1, taking into account the risk of bleeding. Apixaban, dabigatran, edoxaban and rivaroxaban are recommended as options, when used in line with the criteria speci", "score": 0.70702106 } ], "publishedAt": "2026-09-15T21:53:15.765739+00:00", "updatedAt": "2026-09-15T21:53:15.765739+00:00", "readingMinutes": 5, "slug": "af-cardioversion-anticoagulation" }